William Blair analyst Bhavan Suri says Veeva Systems management yesterday introduced "bullish" long-term targets, including a $3B revenue run-rate goal by calendar 2025, indicating 19% annual growth, largely reflective of growth within life sciences offerings. Increased "agility and speed to market capabilities," as well as the continued adoption of Veeva's early stage products, will lead to "multiple years" of greater than 20% revenue growth with "best-in-class" operating margins in excess of 35%, Suri tells investors in a research note. He reiterates an Outperform rating on the shares.